세계의 비강 인플루엔자 백신 시장 보고서(2025년)

Nasal Spray Influenza Vaccine Global Market Report 2025

US $ 4,490 ￦ 6,233,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,010,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,786,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비강 인플루엔자 백신 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 13.1%의 CAGR로 24억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 간편한 예방접종에 대한 수요 증가, 계절성 독감 환자 증가, 정부의 노력과 지원 강화, 고령자 및 고위험군 인구 증가, 의료 환경에서의 백신 채택 확대 등의 요인에 의해 주도될 것으로 예상됩니다. 이 기간의 주요 동향으로는 백신 전달 시스템의 혁신, 점막 면역 전략의 통합, 바이러스 벡터 플랫폼의 기술적 진보, 콜드체인 기술의 발전, mRNA 기술의 도입 등을 꼽을 수 있습니다.

독감 유행이 확대됨에 따라 비강 인플루엔자 백신 시장은 향후 견인차 역할을 할 것으로 예상됩니다. 독감은 전염력이 강한 바이러스 감염으로 주로 호흡기를 침범하여 발열, 기침, 인후통, 몸살, 피로감 등의 증상을 유발합니다. 독감 환자의 증가는 바이러스의 잦은 유전자 변이로 인해 기존 면역력을 벗어나 집단 내에서 빠르게 확산될 수 있기 때문입니다. 비강 인플루엔자 백신은 약독화된 바이러스를 바이러스가 주로 침입하는 비강에 직접 주입하여 면역반응을 유도함으로써 바이러스로부터 자신을 보호할 수 있도록 돕습니다. 예를 들어, 2024년 6월 영국 보건안전국은 2022년 40주에서 2023년 15주 사이에 영국의 108개 NHS 트러스트에서 1,681건의 독감 관련 중증 환자 입원이 확인되었다고 보고했습니다. 이는 지난 시즌의 182건에 비해 크게 증가한 수치입니다. 그 결과, 독감 유행이 확대되면서 비강 인플루엔자 백신 시장 확대에 기여하고 있습니다.

비강 인플루엔자 백신 시장에서 사업을 전개하는 기업들은 면역 반응을 높이고 환자의 순응도를 높이기 위해 약독화 생인플루엔자 백신(LAIV)과 같은 혁신적인 제제 개발에 집중하고 있습니다. 약독화 생백신은 면역체계를 자극하여 항체를 생성하는 약독화 생바이러스로 만들어져 질병을 유발하지 않으면서 예방 효과를 발휘합니다. 이러한 종류의 백신은 국소 면역과 전신 면역을 통해 더 강력한 면역 반응을 일으켜 향후 인플루엔자 감염에 대한 신체의 방어력을 높입니다. 예를 들어, 2024년 9월, 아스트라제네카는 미국 식품의약국(FDA)으로부터 약독성 생인플루엔자 백신(LAIV)인 플루미스트(FluMist)의 승인을 받았습니다. 이 백신은 49세 이하 성인의 자가 접종 또는 2세에서 17세 사이의 소아에게 간병인이 접종할 수 있으며, 자가 접종 또는 간병인 접종이 승인된 미국 최초의 독감백신입니다. 이번 승인은 광범위한 사용성 시험에서 참가자 100%가 지침에 따라 전량 접종할 수 있음을 입증한 데 따른 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 거시경제 시나리오 : 금리·인플레이션·지정학·무역 전쟁·관세·코로나와 회복이 시장에 미치는 영향을 포함한다

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 비강 인플루엔자 백신 시장 : PESTEL 분석(정치·사회·기술·환경·법적 요인, 촉진요인, 억제요인)
• 최종 이용 산업 분석
• 세계의 비강 인플루엔자 백신 시장 : 성장률 분석
• 세계의 비강 인플루엔자 백신 시장 규모·성장률 : 실적치, 2019-2024년
• 세계의 비강 인플루엔자 백신 시장 규모·성장률 : 예측치, 2024-2029년, 2034년
• 세계의 비강 인플루엔자 백신 시장 : 총유효과 시장(TAM)

제6장 시장 세분화

• 세계의 비강 인플루엔자 백신 시장 : 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 생약독화 인플루엔자 백신(LAIV)
• 불활화 인플루엔자 백신
• 세계의 비강 인플루엔자 백신 시장 : 투여 방법별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 일회 투여
• 다회 투여
• 세계의 비강 인플루엔자 백신 시장 : 연령층별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 소아과
• 성인용
• 노인
• 세계의 비강 인플루엔자 백신 시장 : 유통 채널별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 병원
• 클리닉
• 약국
• 온라인 스토어
• 기타 유통 채널
• 세계의 비강 인플루엔자 백신 시장 : 최종사용자별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 의료 제공자
• 개인
• 정부 보건 당국
• 제약 기업
• 세계의 비강 인플루엔자 백신 시장 : 생약독화 인플루엔자 백신(LAIV) 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 3가 생약독화 인플루엔자 백신(3가 LAIV)
• 4가 생약독화 인플루엔자 백신(4가 LAIV)
• 세계의 비강 인플루엔자 백신 시장 : 불활화 인플루엔자 백신 종류별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 전바이러스 불활화 백신
• 스플릿 바이러스 불활화 백신
• 서브유닛 불활화 백신
• 보조제 첨가 불활화 백신
• 고용량 불활화 백신

제7장 지역별·국가별 분석

• 세계의 비강 인플루엔자 백신 시장 : 지역별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년
• 세계의 비강 인플루엔자 백신 시장 : 국가별, 실적치·예측치, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 비강 인플루엔자 백신 시장 : 경쟁 구도
• 비강 인플루엔자 백신 시장 : 기업 개요
  • Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CSL Limited Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Sinovac Biotech Ltd.
• Emergent BioSolutions Inc.
• Serum Institute of India Pvt. Ltd.
• Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
• NPO Microgen JSC
• Changchun BCHT Biotechnology Co. Ltd.
• Mitsubishi Tanabe Pharma Corporation
• FluGen Inc.
• BioDiem Ltd
• Starpharma Holdings Limited
• Codagenix Inc.
• Nobilon International B.V.
• KM Biologics Co. Ltd.
• Altimmune Inc.
• Mylab Discovery Solutions Private Limited

제32장 세계 시장 : 경쟁 벤치마킹·대시보드

제33장 주요 기업 인수합병(M&A)

제34장 최근의 시장 동향

제35장 시장 잠재력 높은 나라·부문과 전략

• 비강 인플루엔자 백신 시장 : 최신 기회를 제공하는 국가(2029년)
• 비강 인플루엔자 백신 시장 : 최신 기회를 제공하는 부문(2029년)
• 비강 인플루엔자 백신 시장 : 성장 전략(2029년)
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

The nasal spray influenza vaccine is a needle-free flu vaccine delivered through the nose, utilizing live attenuated viruses to provide protection against seasonal influenza. It is administered by spraying into the nostrils, where it triggers an immune response in the nasal passages to defend against the flu.

The primary types of nasal spray influenza vaccines are the live attenuated influenza vaccine (LAIV) and the inactivated influenza vaccine. LAIV is a needle-free flu vaccine that uses weakened live viruses to stimulate strong systemic and mucosal immune responses. These vaccines can be administered in single-dose or multi-dose formats and are designed for various age groups, including children, adults, and older adults. Distribution channels include hospitals, clinics, pharmacies, online stores, and other points of sale. End users of nasal spray influenza vaccines consist of healthcare providers, individuals, government health agencies, and pharmaceutical companies.

The nasal spray influenza vaccines market research report is one of a series of new reports from The Business Research Company that provides nasal spray influenza vaccines market statistics, including nasal spray influenza vaccines industry global market size, regional shares, competitors with a nasal spray influenza vaccines market share, nasal spray influenza vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the nasal spray influenza vaccines industry. This nasal spray influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nasal spray influenza vaccine market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to factors such as improved vaccine accessibility, heightened awareness of flu prevention, a growing emphasis on pediatric vaccination, higher vaccination rates, and a greater preference for needle-free vaccines.

The nasal spray influenza vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during the forecast period is expected to be driven by factors such as a rising demand for convenient immunization, an increase in seasonal influenza cases, more government initiatives and support, projected growth in geriatric and high-risk populations, and greater adoption of vaccines in healthcare settings. Key trends during this period include innovations in vaccine delivery systems, the integration of mucosal immunity strategies, technological advancements in viral vector platforms, progress in cold-chain technology, and the incorporation of mRNA technology.

The growing prevalence of influenza is expected to drive the market for nasal spray influenza vaccines in the future. Influenza is a highly contagious viral infection that mainly affects the respiratory system, causing symptoms such as fever, cough, sore throat, body aches, and fatigue. The rise in influenza cases is largely due to the frequent genetic mutations of the virus, allowing it to escape existing immunity and spread quickly through populations. The nasal spray influenza vaccine helps protect against the virus by delivering a weakened form directly into the nasal passages, where the virus typically enters, prompting an immune response. For example, in June 2024, the UK Health Security Agency reported that between week 40 of 2022 and week 15 of 2023, 1,681 confirmed influenza-related critical care admissions were recorded by 108 NHS trusts in England. This was a significant increase compared to 182 admissions the previous season. As a result, the growing prevalence of influenza is contributing to the expansion of the nasal spray influenza vaccine market.

Companies operating in the nasal spray influenza vaccine market are focusing on creating innovative formulations, such as live attenuated influenza vaccines (LAIV), to enhance immune response and improve patient adherence. A live attenuated influenza vaccine is made from live, weakened viruses that stimulate the immune system to produce antibodies, offering protection without causing the disease. This type of vaccine generates a stronger immune response through both local and systemic immunity, which boosts the body's defense against future flu infections. For example, in September 2024, AstraZeneca received approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV). This vaccine can be self-administered by adults up to 49 years old or administered by caregivers to children between 2 and 17 years old, making it the first influenza vaccine in the U.S. approved for self- or caregiver-administration. The approval followed extensive usability studies that showed 100% of participants successfully delivered the full dose as instructed.

In October 2023, Mylab Discovery Solutions, an India-based biotechnology company, partnered with the Serum Institute of India to launch Nasovac S4, India's first nasal influenza vaccine. Through this collaboration, the two companies aim to provide comprehensive protection against various influenza strains with Nasovac S4, a needle-free nasal vaccine. Serum Institute of India is a biotechnology company specializing in nasal influenza vaccines such as Nasovac-S and Nasovac-S4.

Major players in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited

North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nasal spray influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nasal spray influenza vaccine market consists of sales of flumist quadrivalent, fluenz tetra, vaxinate, centripetal flu nasal spray vaccine, nasovac-s, fluvac nasal spray, and live attenuated influenza vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nasal Spray Influenza Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nasal spray influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nasal spray influenza vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nasal spray influenza vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Live Attenuated Influenza Vaccine (LAIV); Inactivated Influenza Vaccine
• 2) By Administration Method: Single-Dose Administration; Multi-Dose Administration
• 3) By Age Group: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Online Stores; Other Distribution Channels
• 5) By End User: Healthcare Providers; Individuals; Government Health Departments; Pharmaceutical Companies
• Subsegments:
• 1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV); Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
• 2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Subunit Inactivated Vaccine; Adjuvanted Inactivated Vaccine; High-Dose Inactivated Vaccine
• Companies Mentioned: Sanofi Pasteur SA; AstraZeneca PLC; GSK plc; Moderna Inc.; CSL Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nasal Spray Influenza Vaccine Market Characteristics

3. Nasal Spray Influenza Vaccine Market Trends And Strategies

4. Nasal Spray Influenza Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nasal Spray Influenza Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nasal Spray Influenza Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nasal Spray Influenza Vaccine Market Growth Rate Analysis
• 5.4. Global Nasal Spray Influenza Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nasal Spray Influenza Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nasal Spray Influenza Vaccine Total Addressable Market (TAM)

6. Nasal Spray Influenza Vaccine Market Segmentation

• 6.1. Global Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Influenza Vaccine (LAIV)
• Inactivated Influenza Vaccine
• 6.2. Global Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Administration
• Multi-Dose Administration
• 6.3. Global Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.4. Global Nasal Spray Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmacies
• Online Stores
• Other Distribution Channels
• 6.5. Global Nasal Spray Influenza Vaccine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healthcare Providers
• Individuals
• Government Health Departments
• Pharmaceutical Companies
• 6.6. Global Nasal Spray Influenza Vaccine Market, Sub-Segmentation Of Live Attenuated Influenza Vaccine (LAIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV)
• Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
• 6.7. Global Nasal Spray Influenza Vaccine Market, Sub-Segmentation Of Inactivated Influenza Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Virus Inactivated Vaccine
• Split Virus Inactivated Vaccine
• Subunit Inactivated Vaccine
• Adjuvanted Inactivated Vaccine
• High-Dose Inactivated Vaccine

7. Nasal Spray Influenza Vaccine Market Regional And Country Analysis

• 7.1. Global Nasal Spray Influenza Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nasal Spray Influenza Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nasal Spray Influenza Vaccine Market

• 8.1. Asia-Pacific Nasal Spray Influenza Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nasal Spray Influenza Vaccine Market

• 9.1. China Nasal Spray Influenza Vaccine Market Overview
• 9.2. China Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nasal Spray Influenza Vaccine Market

• 10.1. India Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nasal Spray Influenza Vaccine Market

• 11.1. Japan Nasal Spray Influenza Vaccine Market Overview
• 11.2. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nasal Spray Influenza Vaccine Market

• 12.1. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nasal Spray Influenza Vaccine Market

• 13.1. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nasal Spray Influenza Vaccine Market

• 14.1. South Korea Nasal Spray Influenza Vaccine Market Overview
• 14.2. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nasal Spray Influenza Vaccine Market

• 15.1. Western Europe Nasal Spray Influenza Vaccine Market Overview
• 15.2. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nasal Spray Influenza Vaccine Market

• 16.1. UK Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nasal Spray Influenza Vaccine Market

• 17.1. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nasal Spray Influenza Vaccine Market

• 18.1. France Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nasal Spray Influenza Vaccine Market

• 19.1. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nasal Spray Influenza Vaccine Market

• 20.1. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nasal Spray Influenza Vaccine Market

• 21.1. Eastern Europe Nasal Spray Influenza Vaccine Market Overview
• 21.2. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nasal Spray Influenza Vaccine Market

• 22.1. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nasal Spray Influenza Vaccine Market

• 23.1. North America Nasal Spray Influenza Vaccine Market Overview
• 23.2. North America Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nasal Spray Influenza Vaccine Market

• 24.1. USA Nasal Spray Influenza Vaccine Market Overview
• 24.2. USA Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nasal Spray Influenza Vaccine Market

• 25.1. Canada Nasal Spray Influenza Vaccine Market Overview
• 25.2. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nasal Spray Influenza Vaccine Market

• 26.1. South America Nasal Spray Influenza Vaccine Market Overview
• 26.2. South America Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nasal Spray Influenza Vaccine Market

• 27.1. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nasal Spray Influenza Vaccine Market

• 28.1. Middle East Nasal Spray Influenza Vaccine Market Overview
• 28.2. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nasal Spray Influenza Vaccine Market

• 29.1. Africa Nasal Spray Influenza Vaccine Market Overview
• 29.2. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Administration Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nasal Spray Influenza Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nasal Spray Influenza Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Nasal Spray Influenza Vaccine Market Competitive Landscape
• 30.2. Nasal Spray Influenza Vaccine Market Company Profiles
  • 30.2.1. Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

31. Nasal Spray Influenza Vaccine Market Other Major And Innovative Companies

• 31.1. Sinovac Biotech Ltd.
• 31.2. Emergent BioSolutions Inc.
• 31.3. Serum Institute of India Pvt. Ltd.
• 31.4. Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
• 31.5. NPO Microgen JSC
• 31.6. Changchun BCHT Biotechnology Co. Ltd.
• 31.7. Mitsubishi Tanabe Pharma Corporation
• 31.8. FluGen Inc.
• 31.9. BioDiem Ltd
• 31.10. Starpharma Holdings Limited
• 31.11. Codagenix Inc.
• 31.12. Nobilon International B.V.
• 31.13. KM Biologics Co. Ltd.
• 31.14. Altimmune Inc.
• 31.15. Mylab Discovery Solutions Private Limited

32. Global Nasal Spray Influenza Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nasal Spray Influenza Vaccine Market

34. Recent Developments In The Nasal Spray Influenza Vaccine Market

35. Nasal Spray Influenza Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Nasal Spray Influenza Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nasal Spray Influenza Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nasal Spray Influenza Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료